RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to launch Naprosyn ES, India's first combination of Naproxen and Esomeprazole, strengthening the companies' existing business relationship and expanding treatment options for patients requiring long-term pain management.

Under the agreement, RPG Life Sciences will exclusively market and distribute Naprosyn ES across India, while Archerchem Healthcare will serve as the exclusive supplier. The product co-developed by Archerchem Healthcare and its development partner, is now available across India.

Naprosyn ES combines the anti-inflammatory benefits of Naproxen with the gastro-protective properties of Esomeprazole, addressing a key unmet need among patients on long-term nonsteroidal anti-inflammatory drug (NSAID) therapy who are at increased risk of gastrointestinal complications.

The differentiated formulation is expected to improve medication adherence while enabling safer long-term pain management, particularly for elderly patients and those with gastrointestinal sensitivity.

Commenting on the launch, Ashok Nair, Managing Director of RPG Life Sciences, said, “At RPG Life Sciences, innovation is rooted in patient centricity. Naprosyn ES is an example of our strong R&D-driven approach to differentiated products, and the long-standing trust that doctors and patients place in the Naprosyn brand.”

Anil Dhedia, Chairman and Managing Director of Archerchem Healthcare, said. “This partnership exemplifies Archerchem's core strength in developing complex differentiated formulations. Through our partnership with RPG Life Sciences, a leading pharmaceutical company with a strong presence across multiple chronic and acute therapies, including pain management, we are proud to deliver incremental innovation that enhances medication adherence and brings meaningful benefits to patients across India.”

RPG Life Sciences plans to leverage the established brand equity of Naprosyn, its extensive engagement with physicians, including super-specialists, and its pan-India distribution network to drive adoption of the new therapy.